Jessica Stroud: Difference between revisions
No edit summary |
No edit summary |
||
| Line 101: | Line 101: | ||
|belowstyle = background: #ddf; | |belowstyle = background: #ddf; | ||
|below = | |below = | ||
}}'''Jessica Kristin Stroud''', PhD (born 6 June 1999) is an American entrepreneur, scientist and sex-positivity advocate who has been serving as Chief Executive Officer of Nimbus Biotechnology Inc. since 5 January 2030. She co-founded the company alongside TBD and TBD. Previously, she worked at Impossible Foods, Inc. from 2026 to 2030, rising to become the director of the company's global research center in April 2029. | }}'''Jessica Kristin Stroud''', PhD (born 6 June 1999) is an American entrepreneur, angel investor, scientist and sex-positivity advocate who has been serving as Chief Executive Officer of Nimbus Biotechnology Inc. since 5 January 2030. She co-founded the company alongside TBD and TBD. Previously, she worked at Impossible Foods, Inc. from 2026 to 2030, rising to become the director of the company's global research center in April 2029. | ||
While still a PhD candidate, Stroud began her career as a research associate with the Good Food Institute in Arlington, Virginia. In 2026, she completed her PhD thesis on alternative proteins and the environmental impact of their widespread adoption. For this, she was awarded the Newcomb Cleveland Prize in 2027. | While still a PhD candidate, Stroud began her career as a research associate with the Good Food Institute in Arlington, Virginia. In 2026, she completed her PhD thesis on alternative proteins and the environmental impact of their widespread adoption. For this, she was awarded the Newcomb Cleveland Prize in 2027. | ||
In January 2030, Stroud left Impossible Foods to start Nimbus with two friends | In January 2030, Stroud left Impossible Foods to start Nimbus with two friends. She initially provided the company's initial startup capital of $1.5 million from her own personal funds. In December that same year, she announced that Nimbus had developed a sublingual drug delivery system based on nanofibers obtained from plants, and had applied for a patent. Under Stroud's leadership, Nimbus has gone on to achieve an annual run-rate revenue of $49 million, and has raised two funding rounds from investors including Quest Ventures, Legend Capital and Nutriven. As of December 2034, Nimbus was valued at $320 million. | ||
<blockquote>'''''<big>"The more successful I become, the more I am aware of the outsized role that luck plays in determining a person's life outcomes. I have been immensely blessed to have had a front-row seat, watching the best and sharpest investors in the world. My husband has helped me immeasurably - more than words can express. I know that not everyone gets these opportunities.</big>''''' | |||
'''''<big>This is why I am determined to make a difference. I want to give back. I want as many young women as possible to experience what I experienced."</big>''''' | |||
<br>'''Jessica Stroud''' | |||
Interview with ''Hong Kong Tatler'' | |||
8 September 2034</blockquote> | |||
Stroud has been married to billionaire investor [[Julian Kao]] since May 2028. Together, they live in a polygamous household with British actress [[Hannah Hazeldon]]. Stroud introduced Hazeldon to Kao in December 2029 and actively encouraged them to date. When Kao took Hazeldon as his second wife in September 2031, Stroud was a maid-of-honor at the wedding ceremony, and delivered one of the keynote speeches. | |||
Both Hazeldon and Stroud have publicly advocated for the full legalization of polygamy, and have argued that it reflects "how nature intended for us to live". Stroud has also stated on multiple occasions that polygamy is beneficial to society, and especially to women, in terms of advancing their social and economic mobility. She has also said that all men with a net worth of $100 million or higher "should be encouraged, or even required" to have a harem. | |||
Stroud is an ardent sex-positivity advocate who believes that "sexual repression is a root cause for many of the world's social problems today". She has publicly supported the full legalization of sex work and denounced the "patriarchal stereotype that women who want to be with wealthy men are gold-diggers and somehow immoral". In 2028, she completed the Complete Submissive course at the Celina Kroes Institute in The Hague. | |||
1 December 2033 | |||
In January 2030, Stroud left Impossible Foods to start Nimbus with two friends, and funded the company's initial startup capital with $1.5 million of her own money. In December that same year, she announced that Nimbus had perfected a sublingual drug delivery system based on nanofibers obtained from plants, and had applied for a patent. In 2031, the company raised $12 million in its Series A round, with investors including Nutriven, Gramercy Ventures and Solo Capital. Subsequently, Nimbus announced a partnership with drug delivery company Hims and Hers to deliver tadalafil and sildenafil (the active ingredients in Cialis and Viagra respectively) using its nanofiber strips. In 2033, the company announced that it had achieved an annual run-rate revenue of $49 million, and was set to double this figure in 2034. In December 2033, the company raised a further $53.5 billion in a Series B round, with investors including Quest Ventures, Legend Capital and IDG Capital. Existing investors Nutriven and Gramercy Ventures also participated in the round.<br> | |||
Revision as of 23:01, 21 April 2025
| Jessica Stroud | |
|---|---|
| Entrepreneur and Business Executive | |
| AS | |
 Jessica Stroud in 2034 | |
| Co-Founder and CEO Nimbus Biotechnology LLC | |
| In Office | 5 Jan 2030 - Present |
| Industry | Biomedical sciences |
| Co-founders | TBD TBD |
| Funding | $53.5 million (Series B, 2033) $12 million (Series A, 2031) |
| Equity | 58.3% |
| 1st President of the Andromeda Sorority | |
| In Office | 5 Nov 2028 - 16 Jan 2030 |
| Patron | Julian Kao |
| Vice President | TBD TBD |
| Preceded by | Position created |
| Succeeded by | Carmen Messina |
| Personal Information | |
| Born | 6 June 1999 (age 35) Cleveland, Ohio United States of America |
| Nationality | .png){kind=small} United States |
| Height | 173 cm (5'8") |
| Breasts | 34C |
| Hair | Blonde |
| Eyes | Blue |
| Dress Size | 6 |
| Education | Northwestern University (BS) Heidelberg University (MSc) UC Berkeley (MS, PhD) |
| Spouse | Julian Kao (m. 2028) |
| Family | Hannah Hazeldon (sister-wife) |
Jessica Kristin Stroud, PhD (born 6 June 1999) is an American entrepreneur, angel investor, scientist and sex-positivity advocate who has been serving as Chief Executive Officer of Nimbus Biotechnology Inc. since 5 January 2030. She co-founded the company alongside TBD and TBD. Previously, she worked at Impossible Foods, Inc. from 2026 to 2030, rising to become the director of the company's global research center in April 2029.
While still a PhD candidate, Stroud began her career as a research associate with the Good Food Institute in Arlington, Virginia. In 2026, she completed her PhD thesis on alternative proteins and the environmental impact of their widespread adoption. For this, she was awarded the Newcomb Cleveland Prize in 2027.
In January 2030, Stroud left Impossible Foods to start Nimbus with two friends. She initially provided the company's initial startup capital of $1.5 million from her own personal funds. In December that same year, she announced that Nimbus had developed a sublingual drug delivery system based on nanofibers obtained from plants, and had applied for a patent. Under Stroud's leadership, Nimbus has gone on to achieve an annual run-rate revenue of $49 million, and has raised two funding rounds from investors including Quest Ventures, Legend Capital and Nutriven. As of December 2034, Nimbus was valued at $320 million.
"The more successful I become, the more I am aware of the outsized role that luck plays in determining a person's life outcomes. I have been immensely blessed to have had a front-row seat, watching the best and sharpest investors in the world. My husband has helped me immeasurably - more than words can express. I know that not everyone gets these opportunities.
This is why I am determined to make a difference. I want to give back. I want as many young women as possible to experience what I experienced."
Jessica StroudInterview with Hong Kong Tatler
8 September 2034
Stroud has been married to billionaire investor Julian Kao since May 2028. Together, they live in a polygamous household with British actress Hannah Hazeldon. Stroud introduced Hazeldon to Kao in December 2029 and actively encouraged them to date. When Kao took Hazeldon as his second wife in September 2031, Stroud was a maid-of-honor at the wedding ceremony, and delivered one of the keynote speeches.
Both Hazeldon and Stroud have publicly advocated for the full legalization of polygamy, and have argued that it reflects "how nature intended for us to live". Stroud has also stated on multiple occasions that polygamy is beneficial to society, and especially to women, in terms of advancing their social and economic mobility. She has also said that all men with a net worth of $100 million or higher "should be encouraged, or even required" to have a harem.
Stroud is an ardent sex-positivity advocate who believes that "sexual repression is a root cause for many of the world's social problems today". She has publicly supported the full legalization of sex work and denounced the "patriarchal stereotype that women who want to be with wealthy men are gold-diggers and somehow immoral". In 2028, she completed the Complete Submissive course at the Celina Kroes Institute in The Hague.
In January 2030, Stroud left Impossible Foods to start Nimbus with two friends, and funded the company's initial startup capital with $1.5 million of her own money. In December that same year, she announced that Nimbus had perfected a sublingual drug delivery system based on nanofibers obtained from plants, and had applied for a patent. In 2031, the company raised $12 million in its Series A round, with investors including Nutriven, Gramercy Ventures and Solo Capital. Subsequently, Nimbus announced a partnership with drug delivery company Hims and Hers to deliver tadalafil and sildenafil (the active ingredients in Cialis and Viagra respectively) using its nanofiber strips. In 2033, the company announced that it had achieved an annual run-rate revenue of $49 million, and was set to double this figure in 2034. In December 2033, the company raised a further $53.5 billion in a Series B round, with investors including Quest Ventures, Legend Capital and IDG Capital. Existing investors Nutriven and Gramercy Ventures also participated in the round.